Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
Q4 2023 vs. Q3 2023
How the institutions holding Oculis Holding AG changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 9 | 7 | −2 |
| Shares | 2.92M | 3.98M | +1.07M (+36.6%) |
| Value | $32.1M | $44.3M | +$12.2M (+37.9%) |
New holders (2)
Institutions that held Oculis Holding AG at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Standard Life Aberdeen plc | 1,452,741 | $16.0M | 0.03% |
| Searle & Co. | 10,000 | $11.0K | 0.00% |
Sold out (4)
Institutions that held Oculis Holding AG at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Wolverine Asset Management LLC | 7,021 | $77.2K |
| UBS Group AG | 2,002 | $22.0K |
| Elequin Capital LP | 300 | $3.30K |
| Tower Research Capital LLC (TRC) | 204 | $2.24K |